Theravance Biopharma, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Theravance Biopharma, Inc. (TBPH) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$10.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-11
- Theravance Biopharma, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$5.90M, a 110.76% decline year-over-year.
- Theravance Biopharma, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$4.93M.
- Theravance Biopharma, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $61.02M.
- Theravance Biopharma, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $3.62M.
- Theravance Biopharma, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was $105.89M.
- Theravance Biopharma, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$56.42M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$10.83M 10-Q · filed 2026-08-11 | $50.19M derived: sum of 3 quarters · filed 2026-08-11 | $53.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$4.93M 10-Q · filed 2026-05-07 | $56.09M derived: sum of 2 quarters · filed 2026-05-07 | $59.71M derived: sum of 3 quarters · filed 2026-05-07 | $114.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $61.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $64.64M derived: sum of 2 quarters · filed 2026-03-23 | $119.47M derived: sum of 3 quarters · filed 2026-08-11 | $105.89M 10-K · filed 2026-03-23 |
| 2025-09-30 | $3.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $58.45M derived: sum of 2 quarters · filed 2026-08-11 | $44.87M 10-Q · filed 2025-11-12 | $29.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $54.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $41.26M 10-Q · filed 2026-08-11 | $25.73M derived: sum of 3 quarters · filed 2026-08-11 | $13.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$13.58M 10-Q · filed 2026-05-07 | -$29.11M derived: sum of 2 quarters · filed 2026-05-07 | -$41.80M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$15.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$28.23M derived: sum of 2 quarters · filed 2026-03-23 | -$56.42M 10-K · filed 2026-03-23 | |
| 2024-09-30 | -$12.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$40.89M 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | -$28.19M 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |